On June 3rd 2020 GVS S.p.A. signed an agreement to acquire Haemonetics’ plant in Fajardo and to supply and develop blood filters for Haemonetics
Today our Group announced that it has entered into an agreement to acquire Haemonetics’ Fajardo, Puerto Rico, manufacturing operations and to supply and develop blood filters for Haemonetics.
The combination of the companies’ respective technical expertise, global sales and distribution networks will provide GVS an opportunity to further penetrate the blood filtration market. The partnership will further strengthen the relationship between the Companies, create mutually beneficial synergies and leverage the unique capabilities of both organizations
GVS will provide its blood filtration know-how and industrial process excellence and Haemonetics its global commercial network. As a result of this partnership, the two Companies will strengthen their leadership position in the market and will boost the development of new products and new approaches to the business.
"We are honored that Haemonetics, an industry leader and one of our long-term clients, has chosen GVS for this strategic partnership, which is testament to our technological and process capabilities," stated Massimo Scagliarini, CEO of GVS. "This collaboration will provide us with a new channel for R&D, stimulating the introduction of new products, ideas and solutions for the blood filtration market."
"We continue to pursue operational excellence to offer our customers high quality products through an asset-lite approach," said Chris Simon, Haemonetics’ President and CEO. "We are confident that GVS’ experience and scale in filtration will help us deliver reliable, cost-efficient products."
